Protea, InSphero Collaborate on 3D Technologies for Pharmacokinetics, Toxicity Research | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences and InSphero today said they will combine their 3D technologies into new products and services to be marketed to the pharmaceutical and biotechnology markets.

The collaboration will use Protea's proprietary LAESI direct molecular imaging platform to analyze InSphero's 3D InSight microtissues, resulting in 3D molecular profiles for tissue characterization, drug metabolism and distribution, pharmacokinetic, and toxicity applications, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.